Balanced news tone
News Sentiment
BMY sentiment intelligence
Bristol-Myers Squibb Company news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
53
Balanced news tone
25 relevant articles
News tone and price action are not far from neutral.
84/100 classification confidence.
directly relevant articles
high-authority source matches
-2.1% over one week, -6.0% over four weeks, trend inactive, and materially above fair value.
Why is Barclays Bullish on Bristol-Myers Squibb (BMY) Now
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Primary event
Market update
84/100 classification
One-week reaction
-2.1%
Price reacting lower
Trend fit
Trend inactive
-6.0% over four weeks
Fair value
31.7%
Materially above fair value
Sentiment Mix
Positive, neutral, negative
Positive
6
Neutral
18
Negative
1
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Kavout
Direct company coverage
Why is Barclays Bullish on Bristol-Myers Squibb (BMY) Now
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 20 Jun 2026 23:44
- Source
- Kavout
Fortune
Direct company coverage
Bristol-Myers Squibb (BMY) Q1 2026 Earnings Call Transcript
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 19 Jun 2026 23:05
- Source
- Fortune
GuruFocus
Direct company coverage
Bristol-Myers Squibb (BMY) Maintains Quarterly Dividend at $0.63 per Share
- Tone
- Neutral 50/100
- Event
- Capital return
- Published
- 18 Jun 2026 06:16
- Source
- GuruFocus
Market source
Direct company coverage
Bristol Myers Squibb (BMY) Stock Could Be 12.2% Undervalued on Pipeline and Margin Hopes
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 17 Jun 2026 23:20
- Source
- Market source
Market source
Direct company coverage
Bristol Myers Squibb (BMY) Stock Moves -1.14%: What You Should Know
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Jun 2026 21:45
- Source
- Market source
Business Wire
Direct company coverage
Bristol Myers Squibb Announces Dividend
- Tone
- Neutral 50/100
- Event
- Capital return
- Published
- 17 Jun 2026 20:16
- Source
- Business Wire
Yahoo! Finance Canada
Direct company coverage
Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Jun 2026 13:00
- Source
- Yahoo! Finance Canada
simplywall.st
Direct company coverage
Bristol Myers Squibb (BMY) Stock Could Be 10.7% Undervalued After Kidney Cancer Trial Expansion
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 16 Jun 2026 11:37
- Source
- simplywall.st
Barchart.com
Direct company coverage
BMY Price History for Bristol-Myers Squibb Company Stock
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Jun 2026 07:00
- Source
- Barchart.com
IndexBox
Direct company coverage
Bristol Myers Squibb Dividend Analysis: Patent Cliff Risks and Financial Strength in 2026 - News and Statistics
- Tone
- Negative 34/100
- Event
- Capital return
- Published
- 11 Jun 2026 18:50
- Source
- IndexBox
Market source
Direct company coverage
Better High-Yield Dividend Stock to Buy: Bristol Myers Squibb or Pfizer?
- Tone
- Positive 66/100
- Event
- Capital return
- Published
- 04 Jun 2026 07:00
- Source
- Market source
Seeking Alpha
Direct company coverage
Bristol Myers Squibb: This Pullback Is A Gift For Long-Term Investors (NYSE:BMY)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jun 2026 07:00
- Source
- Seeking Alpha
Barchart.com
Direct company coverage
Is Bristol-Myers Squibb Stock Underperforming the Dow?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jun 2026 07:00
- Source
- Barchart.com
Market source
Direct company coverage
Spotting Winners: Bristol-Myers Squibb (NYSE:BMY) And Branded Pharmaceuticals Stocks In Q1
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Jun 2026 07:00
- Source
- Market source
Market source
Direct company coverage
Why Bristol Myers Squibb Stock Isn't Nearly As Cheap As It Looks
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Jun 2026 07:00
- Source
- Market source
Market source
Direct company coverage
Here's Why Bristol Myers Squibb (BMY) is a Strong Value Stock
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 26 May 2026 07:00
- Source
- Market source
CHEManager
Direct company coverage
Bristol Myers Squibb Bolsters Oncology Pipeline with Lonza Licensing Agreement
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 May 2026 07:00
- Source
- CHEManager
Trefis
Direct company coverage
5-Day Sell-Off Sends Bristol-Myers Squibb Stock Down -7.2%
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 May 2026 07:00
- Source
- Trefis
IndexBox
Direct company coverage
Bristol Myers Squibb Stock Gains 20% Amid 2026 Revenue Outlook
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 27 Apr 2026 07:00
- Source
- IndexBox
IndexBox
Direct company coverage
Why Investors Hold Medtronic, Sanofi, and Bristol Myers Squibb for Dividends - News and Statistics
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Apr 2026 07:00
- Source
- IndexBox
Market source
Direct company coverage
Why Bristol Myers Squibb (BMY) Outpaced the Stock Market Today
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Apr 2026 07:00
- Source
- Market source
Market source
Direct company coverage
Is Bristol-Myers Squibb Company (BMY) A Good Stock To Buy Now?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 29 Mar 2026 07:00
- Source
- Market source
StockStory
Direct company coverage
Why Bristol-Myers Squibb (BMY) Stock Is Up Today
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Mar 2026 07:00
- Source
- StockStory
IndexBox
Direct company coverage
Bristol Myers Squibb: A Defensive Dividend Stock for Volatile Markets - News and Statistics
- Tone
- Neutral 50/100
- Event
- Capital return
- Published
- 21 Mar 2026 07:00
- Source
- IndexBox
Pharmaceutical Technology
Direct company coverage
Bristol Myers Squibb agrees to acquire RPT company RayzeBio for $4.1bn
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Dec 2023 08:00
- Source
- Pharmaceutical Technology